Literature DB >> 8590978

Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors.

J L Boyer1, J W O'Tuel, B Fischer, K A Jacobson, T K Harden.   

Abstract

1. Analogues of adenine nucleotides inhibited beta-adrenoceptor-stimulated cyclic AMP accumulation in C6 rat glioma cells with a pharmacological selectivity consistent with that for involvement of a P2Y-purinoceptor. 2. The inhibitory effect of adenine nucleotides was completely prevented by pretreatment of cells with pertussis toxin. 3. The capacity of a series of recently synthesized 2-thioether analogues of adenine nucleotides to inhibit cyclic AMP accumulation was examined. Several ATP analogues, e.g. 2-cyclohexylthio and 2-hexylthio ATP, inhibited cyclic AMP accumulation with EC50 values of approximately 30 pM. These values represent 100,000 fold increases in potency over ATP. 4. Analogues of ADP exhibited the same remarkable increase in potency relative to their natural congener and diphosphates were at least as potent as the corresponding triphosphates at the C6 cell P2Y-purinoceptor. 5. The relative potencies of a broad series of agonists at the C6 cell receptor did not correspond to the relative potencies of the same compounds for activation of P2Y-purinoceptors on turkey erythrocyte membranes. Some agonists, particularly 2-thioether derivatives were more potent for stimulation of the C6 cell receptor, whereas other agonists were more potent in the turkey erythrocyte system. 6. These results add further support to the view that the adenylyl cyclase-linked P2Y-purinoceptor of C6 rat glioma cells is a different subtype from the phospholipase C-linked P2Y-purinoceptor of turkey erythrocyte membranes and several mammalian tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590978      PMCID: PMC1909117          DOI: 10.1111/j.1476-5381.1995.tb17215.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP.

Authors:  S Valera; N Hussy; R J Evans; N Adami; R A North; A Surprenant; G Buell
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

Review 2.  P2-purinergic receptors: subtype-associated signaling responses and structure.

Authors:  T K Harden; J L Boyer; R A Nicholas
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

Review 3.  Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides.

Authors:  G R Dubyak; C el-Moatassim
Journal:  Am J Physiol       Date:  1993-09

Review 4.  Nomenclature and classification of purinoceptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; J W Daly; T K Harden; K A Jacobson; P Leff; M Williams
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

5.  The ATP4- receptor of rat mast cells.

Authors:  S Cockcroft; B D Gomperts
Journal:  Biochem J       Date:  1980-06-15       Impact factor: 3.857

6.  Expression of a cloned P2Y purinergic receptor that couples to phospholipase C.

Authors:  T M Filtz; Q Li; J L Boyer; R A Nicholas; T K Harden
Journal:  Mol Pharmacol       Date:  1994-07       Impact factor: 4.436

7.  Endothelin- and ATP-induced inhibition of adenylyl cyclase activity in C6 glioma cells: role of Gi and calcium.

Authors:  W W Lin; D M Chuang
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

8.  Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors.

Authors:  J L Boyer; I E Zohn; K A Jacobson; T K Harden
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

9.  Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase.

Authors:  J L Boyer; E R Lazarowski; X H Chen; T K Harden
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

10.  New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor.

Authors:  A J Brake; M J Wagenbach; D Julius
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

View more
  7 in total

Review 1.  Nucleotide receptors in the nervous system. An abundant component using diverse transduction mechanisms.

Authors:  E A Barnard; J Simon; T E Webb
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

2.  Two subtypes of G protein-coupled nucleotide receptors, P2Y(1) and P2Y(2) are involved in calcium signalling in glioma C6 cells.

Authors:  P Sabala; R Czajkowski; K Przybyłek; K Kalita; L Kaczmarek; J Barańska
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

4.  Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate.

Authors:  J L Boyer; S Siddiqi; B Fischer; T Romero-Avila; K A Jacobson; T K Harden
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist.

Authors:  José L Boyer; Mary Adams; R Gnana Ravi; Kenneth A Jacobson; T Kendall Harden
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

6.  Pharmacological characterisation of the P2Y11 receptor in stably transfected haematological cell lines.

Authors:  L van der Weyden; D J Adams; B M Luttrell; A D Conigrave; M B Morris
Journal:  Mol Cell Biochem       Date:  2000-10       Impact factor: 3.396

7.  Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor.

Authors:  J B Schachter; Q Li; J L Boyer; R A Nicholas; T K Harden
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.